The full content of Annals is available to subscribers

Subscribe/Learn More  >
Brief Communications |

Prevention of Mast-Cell Degranulation by Ketotifen in Patients with Physical Urticarias

[+] Article, Author, and Disclosure Information

Grant support: in part by grant AI00519 from the National Institute of Allergy and Infectious Diseases, and grant RR-00350 from the National Institutes of Health to the General Clinical Research Center at the Methodist Hospital and Baylor College of Medicine. Dr. Huston is the recipient of a Clinical Investigator Award from the National Institute of Allergy and Infectious Diseases.

Presented in part at the national meeting of the American Federation for Clinical Research, Washington, D.C., 1985.

▸Requests for reprints should be addressed to David P. Huston, M.D.; The Methodist Hospital, 6565 Fannin Street, M.S. F-501; Houston, TX 77030.

Houston, Texas; and Bethesda, Maryland

©1986 American College of PhysiciansAmerican College of Physicians

Ann Intern Med. 1986;104(4):507-510. doi:10.7326/0003-4819-104-4-507
Text Size: A A A

The capacity for ketotifen to prevent mast-cell degranulation in vivo was studied in patients with physical urticarias. Patients were exposed to the appropriate stimulus to elicit their physical urticaria before and during ketotifen therapy. Histamine concentrations in plasma samples, obtained before and serially after the physical provocation, were determined by radioenzymatic thin-layer chromatography. Ketotifen therapy was associated with marked reductions in plasma histamine levels after stimulation and in clinical evidence of urticaria in each patient. A direct correlation of ketotifen therapy and a reduction in histamine release was confirmed in a patient with a cold-induced urticaria who was studied again after discontinuation and again after reinstitution of therapy. Although the mechanism of action is unknown, this report shows that ketotifen is capable of inhibiting cutaneous mast-cell degranulation and its accompanying symptoms. These findings suggest important therapeutic alternatives for patients with mast-cell-mediated diseases.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $42.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.